Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka, Salomon Manier, Natalie Callander, Luciano J Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R Solomon, Michel Delforge, Jesus Berdeja, Anna Truppel-Hartmann, Zhihong Yang, Linda Favre-Kontula, Fan Wu, Julia Piasecki, Mark Cook, Sergio Giralt
WHAT IS THIS SUMMARY ABOUT?: This plain language summary describes the results of a Phase 3 study called KarMMa-3. In this ongoing study, researchers looked at a relatively new treatment for people with multiple myeloma, a type of blood cancer, whose cancer got worse despite treatment (refractory) or had cancer that at first improved with treatment, but eventually stopped responding (relapsed). HOW WAS THIS STUDY CONDUCTED?: In the KarMMa-3 study, people with relapsed or refractory multiple myeloma received either a one-time infusion of a new treatment, named ide-cel, or one of the standard of care regimens currently available for patients with this cancer...
April 23, 2024: Future Oncology